Molecular Insights and Therapeutic Advances in Hematological Disorders
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 687
Special Issue Editor
Interests: hematologic malignancies; thrombosis; complement; cellular therapy; lymphoma; myeloma; COVID-19
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, many advances have been made in the understanding of the pathophysiology behind various hematological disorders. A better understanding of the molecular biology of both benign, such as hemoglobinopathies and congenital bleeding disorders, and malignant hematological diseases has led to the development of targeted therapeutics. For example, since the discovery of the Philadelphia chromosome in patients with chronic myelogenous leukemia and the development and approval of Imatinib, a tyrosine kinase inhibitor (TKI), the management of this clinical entity has been revolutionized. Moreover, the involvement of the immune system has been recognized in the pathogenesis of many hematological diseases. Specifically, complement system activation has been described as pathogenic in various disorders, such as paroxysmal nocturnal hemoglobinuria (PNH). Immune dysregulation is also prevalent in hematological malignancies, while immune therapeutics, including chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies, constitute nowadays a standard of care for patients with refractory/relapsed B-cell lymphoproliferative neoplasms and multiple myeloma. The interaction between coagulation, immunity, and vascular endothelium is an emerging issue, concerning not only hematological disorders but also the complications of hematopoietic stem cell transplantation and novel immune therapeutics. This Special Issue aims to publish cutting-edge communication, research, and review articles concerning the pathophysiology, molecular biology, and novel therapeutics about, but not limited to, the following clinical entities: acute leukemia; myeloproliferative neoplasms; lymphoma; multiple myeloma; hemoglobinopathies; and hemophilia.
Notably, we also want to thank the journal’s Topical Advisory Panel Member, Dr. Nikolaos Kotsiou, for his contribution and support to the concept proposal, collaboration promotion, Special Issue operation, and development of this Special Issue.
Dr. Eleni Gavriilaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute leukemia
- myeloproliferative neoplasms
- lymphoma
- multiple myeloma
- hemoglobinopathies
- hemophilia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
